Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coppo R, D’Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford classification for IgA nephropathy (VALIGA) update. Nephrol Dial Transplant. 2020;35(6):1002–9.

Article  CAS  PubMed  Google Scholar 

Knoop T, Vikse BE, Mwakimonga A, Leh S, Bjørneklett R. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant. 2017;32(11):1841–50.

Article  CAS  PubMed  Google Scholar 

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1–276.

Article  Google Scholar 

Cheung CK, Rajasekaran A, Barratt J, Rizk DV. An update on the current state of management and clinical trials for IgA nephropathy. J Clin Med. 2021;10(11):2493.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044–52.

Article  CAS  PubMed  Google Scholar 

Lv J, Zhang H, Perkovic V. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy. JAMA. 2017;318(5):432–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure a meta-analysis. JAMA. 2016;315(2):164–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Evaluating a new International Risk-Prediction Tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–52.

Roberts ISD, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56.

Article  PubMed  Google Scholar 

Rottenstreich A. Bleeding risk assessment and the role of primary hemostasis screening in patients undergoing kidney biopsy. Isr Med Assoc J. 2018;20(August):499–503.

PubMed  Google Scholar 

Charu V, O’Shaughnessy MM, Chertow GM, Kambham N. Percutaneous kidney biopsy and the utilization of blood transfusion and renal angiography among hospitalized adults. Kidney Int Rep. 2019;4(10):1435–45.

Article  PubMed  PubMed Central  Google Scholar 

Bandari J, Fuller TW, Turner RM II, D’Agostino LA. Renal biopsy for medical renal disease: indications and contraindications. Can J Urol. 2016;23(1):8121–6.

PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, Antes G, Atkins D, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

Moons KG, Hooft L, Williams K, Hayden JA, Damen JA, Riley RD. Implementing systematic reviews of prognosis studies in Cochrane. The Cochrane Database Syst Rev. 2018;10:ED000129.

PubMed  Google Scholar 

Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1–33.

Article  PubMed  Google Scholar 

Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, et al. Conversion of urine protein–creatinine ratio or urine dipstick protein to urine albumin–creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant–based meta-analysis. Ann Intern Med. 2020;173(6):426–35.

Article  PubMed  PubMed Central  Google Scholar 

Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350(870).

Ouyang Y, Zhao Z, Li G, Luo H, Xu F, Shao L, et al. A validation study comparing risk prediction models of IgA nephropathy. Front Immunol. 2021;15:12.

Google Scholar 

O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant. 2018;33(4):661–9.

Article  PubMed  Google Scholar 

Ali I, Donne RL, Kalra PA. A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility. BMC Nephrol. 2021;22(1).

Shi SF, Wang SX, Jiang L, Ji-Cheng L, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification. Clin J Am Soc Nephrol. 2011;6(9):2175–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Tsuchimoto A, Noguchi H, et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013;8(12):2082–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.

Article  PubMed  Google Scholar 

Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6:2806–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011;6(10):2384–8.

Article  PubMed  PubMed Central  Google Scholar 

Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7(6):e38904.

McQuarrie EP, Mackinnon B, McNeice V, Fox JG, Geddes CC. The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation. Kidney Int. 2014;85(1):198–203.

Article  PubMed  Google Scholar 

Burke JP, Pham T, May S, Okano S, Ratanjee SK, Thet Z, et al. Kidney biopsy practice amongst Australasian nephrologists. BMC Nephrol. 2021;22(1):291.

Kawaguchi T, Nagasawsa T, Tsuruya K, Miura K, Katsuno T, Morikawa T, et al. A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan. Clin Exp Nephrol. 2020;24(5):389–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jullien P, Laurent B, Berthoux F, Masson I, Dinic M, Claisse G, et al. Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome. Nephrol Dial Transplant. 2020;35(7):1179–86.

Article  CAS  PubMed  Google Scholar 

Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 2022;102(1):160–72.

Article  CAS  PubMed  Google Scholar 

Ramspek CL, de Jong Y, Dekker FW, van Diepen M. Towards the best kidney failure prediction tool: a systematic review and selection aid. Nephrol Dial Transplant. 2020;35(9):1527–38.

Article  PubMed  Google Scholar 

Lim DKE, Boyd JH, Thomas E, Chakera A, Tippaya S, Irish A, et al. Prediction models used in the progression of chronic kidney disease: a scoping review, vol. 17. PLoS ONE: Public Library of Science; 2022.

Google Scholar 

Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts ISD, Feehally J, et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int. 2016;89(1):167–75.

Article  CAS  PubMed  Google Scholar 

Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):752–61.

Article  PubMed